BRPI0910461B8 - hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso - Google Patents

hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Info

Publication number
BRPI0910461B8
BRPI0910461B8 BRPI0910461A BRPI0910461A BRPI0910461B8 BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8 BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8
Authority
BR
Brazil
Prior art keywords
production method
stimulating hormone
follicle stimulating
pharmaceutical composition
recombinant follicle
Prior art date
Application number
BRPI0910461A
Other languages
English (en)
Inventor
Plaksin Daniel
Cottingham Ian
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910461(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of BRPI0910461A2 publication Critical patent/BRPI0910461A2/pt
Publication of BRPI0910461A8 publication Critical patent/BRPI0910461A8/pt
Publication of BRPI0910461B1 publication Critical patent/BRPI0910461B1/pt
Publication of BRPI0910461B8 publication Critical patent/BRPI0910461B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

hormônio de estimulação do folículo (fhs) recombinante incluindo sialilação alfa 2,3 e alfa 2,6, suas preparações e composições farmacêuticas, uso dos mesmos na fabricação de medicamentos, e método de produção do rfsh. a presente invenção refere-se a preparação incluindo fsh recombinante (rfsh).
BRPI0910461A 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso BRPI0910461B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (4)

Publication Number Publication Date
BRPI0910461A2 BRPI0910461A2 (pt) 2018-03-27
BRPI0910461A8 BRPI0910461A8 (pt) 2018-10-16
BRPI0910461B1 BRPI0910461B1 (pt) 2021-02-23
BRPI0910461B8 true BRPI0910461B8 (pt) 2021-05-25

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910461A BRPI0910461B8 (pt) 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Country Status (29)

Country Link
US (5) US8951967B2 (pt)
EP (7) EP3098234A1 (pt)
JP (7) JP2011519359A (pt)
KR (5) KR20160056960A (pt)
CN (3) CN105906703A (pt)
AR (1) AR071479A1 (pt)
AU (5) AU2009237479B2 (pt)
BR (1) BRPI0910461B8 (pt)
CA (1) CA2725257A1 (pt)
CY (1) CY1115413T1 (pt)
DK (4) DK2808340T3 (pt)
ES (3) ES2468318T3 (pt)
FR (1) FR17C1020I2 (pt)
HK (2) HK1146284A1 (pt)
HR (3) HRP20140535T1 (pt)
HU (5) HUE033830T2 (pt)
IL (2) IL208538A (pt)
LT (4) LT2808340T (pt)
MX (3) MX2010011343A (pt)
NO (2) NO2017025I1 (pt)
NZ (1) NZ588381A (pt)
PL (4) PL2268666T3 (pt)
PT (4) PT3144318T (pt)
RU (3) RU2682270C2 (pt)
SA (1) SA109300228B1 (pt)
SI (4) SI2808340T1 (pt)
TW (1) TWI488640B (pt)
WO (1) WO2009127826A1 (pt)
ZA (1) ZA201007373B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2848687B1 (en) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Novel expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
JP7079094B2 (ja) 2015-04-17 2022-06-01 フェリング ベスローテン フェンノートシャップ 不妊症の処置のための組成物
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
ES2904787T3 (es) 2017-09-01 2022-04-06 Ferring Bv Composición para la estimulación ovárica controlada
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
KR20210079276A (ko) 2018-10-17 2021-06-29 훼링 비.브이. 제어된 난소 자극을 위한 조성물 및 방법
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
WO1998031826A1 (en) 1997-01-16 1998-07-23 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
ATE332705T1 (de) 1999-05-07 2006-08-15 Applied Research Systems Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
RS32804A (en) * 2001-10-22 2007-02-05 Applied Research Systems Ars Holding N.V., Gonadotrophins for folliculogenesis
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
BR112016023668A2 (pt) 2014-04-18 2017-10-17 Glycotope Gmbh hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Also Published As

Publication number Publication date
BRPI0910461B1 (pt) 2021-02-23
TW200948378A (en) 2009-12-01
JP6762916B2 (ja) 2020-09-30
LTPA2017018I1 (lt) 2017-06-26
LT3045471T (lt) 2017-07-10
CN102066414A (zh) 2011-05-18
IL230571A (en) 2015-11-30
RU2014141994A3 (pt) 2018-05-28
DK2808340T3 (en) 2016-12-05
EP2268666A1 (en) 2011-01-05
HRP20140535T1 (hr) 2014-07-18
US9771407B2 (en) 2017-09-26
RU2745557C3 (ru) 2021-12-10
JP2022031652A (ja) 2022-02-22
DK3144318T3 (da) 2020-12-07
US10995128B2 (en) 2021-05-04
PT3144318T (pt) 2020-11-04
US20180079794A1 (en) 2018-03-22
WO2009127826A1 (en) 2009-10-22
KR20180095140A (ko) 2018-08-24
PT3045471T (pt) 2017-06-14
EP3045471B1 (en) 2017-03-29
KR101622944B1 (ko) 2016-05-23
JP2011519359A (ja) 2011-07-07
EP4015527A1 (en) 2022-06-22
AU2014203277C1 (en) 2017-07-27
AU2017204258A1 (en) 2017-07-20
JP2015120696A (ja) 2015-07-02
RU2682270C2 (ru) 2019-03-18
ES2468318T3 (es) 2014-06-16
MX355457B (es) 2018-04-19
HRP20161520T1 (hr) 2016-12-30
HK1199039A1 (en) 2015-06-19
JP2020040956A (ja) 2020-03-19
RU2010141908A (ru) 2012-05-27
JP2024038000A (ja) 2024-03-19
US20110105398A1 (en) 2011-05-05
CN105906702A (zh) 2016-08-31
PL3144318T3 (pl) 2021-02-08
AU2017204259A1 (en) 2017-07-20
US20210332099A1 (en) 2021-10-28
EP2268666B1 (en) 2014-03-12
AU2014203277A1 (en) 2014-07-24
KR102108377B1 (ko) 2020-05-08
PL3045471T3 (pl) 2017-10-31
EP2722339A1 (en) 2014-04-23
US20150065695A1 (en) 2015-03-05
BRPI0910461A2 (pt) 2018-03-27
ZA201007373B (en) 2011-06-29
HUE030652T2 (en) 2017-05-29
AR071479A1 (es) 2010-06-23
DK3045471T3 (en) 2017-06-26
SI2808340T1 (sl) 2016-12-30
US11952407B2 (en) 2024-04-09
RU2745557C1 (ru) 2021-03-29
FR17C1020I1 (pt) 2020-04-10
HUE033830T2 (en) 2018-01-29
RU2014141994A (ru) 2016-05-10
AU2009237479B2 (en) 2014-05-15
JP2018021037A (ja) 2018-02-08
EP3098234A1 (en) 2016-11-30
NO2017050I1 (no) 2017-09-28
JP7316905B2 (ja) 2023-07-28
CN105906703A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
ES2610277T3 (es) 2017-04-26
HUS1700036I1 (hu) 2017-10-30
SI3144318T1 (sl) 2020-12-31
JP6486310B2 (ja) 2019-03-20
DK2268666T3 (da) 2014-05-12
KR20160056960A (ko) 2016-05-20
EP3144318A1 (en) 2017-03-22
PL2268666T3 (pl) 2014-08-29
KR20110005863A (ko) 2011-01-19
EP2808340A1 (en) 2014-12-03
SA109300228B1 (ar) 2014-04-08
RU2537268C2 (ru) 2014-12-27
LT2808340T (lt) 2016-11-10
NZ588381A (en) 2012-05-25
US20160347811A1 (en) 2016-12-01
HUE030652T4 (en) 2017-09-28
PL2808340T3 (pl) 2017-02-28
AU2017225020A1 (en) 2017-09-28
KR20170110741A (ko) 2017-10-11
PT2268666E (pt) 2014-06-25
AU2017204258B2 (en) 2017-08-17
MX348622B (es) 2017-06-22
IL208538A (en) 2014-03-31
IL208538A0 (en) 2010-12-30
HK1146284A1 (en) 2011-05-20
US8951967B2 (en) 2015-02-10
HUS1700025I1 (hu) 2017-06-28
LTPA2017029I1 (lt) 2017-10-10
AU2017225020B2 (en) 2019-11-14
ES2629392T3 (es) 2017-08-09
NO2017025I1 (no) 2017-06-06
US9546204B2 (en) 2017-01-17
CY1115413T1 (el) 2017-01-04
PT2808340T (pt) 2016-11-21
AU2009237479A1 (en) 2009-10-22
EP3144318B1 (en) 2020-09-23
TWI488640B (zh) 2015-06-21
AU2017204259B2 (en) 2017-08-17
CA2725257A1 (en) 2009-10-22
AU2014203277B2 (en) 2017-04-06
BRPI0910461A8 (pt) 2018-10-16
MX2010011343A (es) 2011-01-20
HRP20170958T1 (hr) 2017-09-22
KR20190092608A (ko) 2019-08-07
SI3045471T1 (sl) 2017-07-31
HUS1700024I1 (hu) 2017-06-28
FR17C1020I2 (fr) 2020-04-10
EP2808340B1 (en) 2016-08-17
JP2017060476A (ja) 2017-03-30
SI2268666T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
TN2012000478A1 (en) Long - acting formulations of insulins
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
UY27720A1 (es) Aroilpiridinonas monocíclicas,
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
NZ702801A (en) Treatment of sanfilippo syndrome type b
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
RS54905B1 (sr) Poboljšani rekombinantni humani folikulo-stimulišući hormon
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
BR112022012063A2 (pt) Comprimidos de edoxabana
BRPI0908569B8 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF